Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc.: A Critical Look for Investors

Welcome to an investor's guide to Semnur Pharmaceuticals, Inc.'s past year. We'll cut through the corporate jargon to deliver the essential facts about their business, financial health, key events, and future prospects. Be prepared for a candid assessment of a company facing significant challenges.

1. Business Overview

Semnur Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, developing product candidates for pain management. The company you see today emerged from a significant corporate transformation in 2025.

• The Big Change: On September 22, 2025, Denali Capital Acquisition Corp., a public shell company, completed a merger (known as a "Business Combination") with a private entity, Legacy Semnur. Denali then rebranded as Semnur Pharmaceuticals, Inc., with Legacy Semnur becoming its wholly-owned subsidiary. This merger effectively brought the private Semnur's operations into the public market.
• Core Focus: Semnur's primary asset is SP-102, an investigational epidural steroid injection designed to treat sciatica. The company aims to pursue the Section 505(b)(2) regulatory pathway for SP-102. This pathway could potentially expedite FDA approval by allowing Semnur to rely on the FDA's previous findings of safety and effectiveness for an already approved drug, thereby reducing the need for extensive new clinical trials.
• Market Listing Shift: A notable event occurred on April 16, 2025, when the company delisted from The Nasdaq Capital Market. Its shares began trading on the OTCQB marketplace the very next day. After the merger, the stock symbols became "SMNR" and "SMNRW." This move from a major exchange like Nasdaq to the OTCQB typically signals reduced visibility, lower trading volume (liquidity), less analyst coverage, and potentially higher price volatility, which can make shares harder to buy or sell.
• Company Size: As of June 30, 2025, the total value of voting stock available to public investors (the "public float") stood at a mere $0.5 million. This classifies Semnur as a "micro-cap" stock, indicating a very small company with inherently higher risks and potential volatility.
• Regulatory Status: Semnur qualifies as both an Emerging Growth Company (EGC) and a Smaller Reporting Company (SRC). This status grants certain benefits, such as reduced reporting requirements and exemptions from some regulatory mandates, which can lower compliance costs.

2. Financial Performance

Semnur Pharmaceuticals faced severe financial challenges in 2025, marked by a complete absence of product revenue and substantial operating losses.

• No Product Revenue: The company generated no product revenue in 2025, as SP-102 remains in development.
• Operating and Net Losses: Semnur reported a massive operating loss of $160.4 million in 2025, a dramatic increase from $4.69 million in 2024. The net loss for 2025 also totaled $160.4 million, compared to $4.69 million in 2024. These figures indicate significant cash burn and operational expenses far exceeding any income.
• Accumulated Deficit: The company's total accumulated losses since inception reached a staggering $275.8 million as of December 31, 2025, reflecting years of development costs without commercialized products.
• Operating Expenses Breakdown:
  • Research and Development (R&D): R&D expenses increased to $2.5 million in 2025 from $1.7 million in 2024 (a 47% increase). This $0.8 million rise primarily stemmed from increased personnel and activities related to advancing SP-102.
  • General and Administrative (G&A): This category saw an extraordinary jump, skyrocketing to $157.9 million in 2025 from just $3.0 million in 2024 (a 5,163% increase). The vast majority of this $154.9 million increase resulted from:
    • $140.0 million in non-cash consulting expenses related to shares issued to consultants upon the merger's closing.
    • $9.9 million in deferred offering costs that the company wrote off as expenses when the merger closed.
    • Increased costs for personnel and consultants needed to operate as a public company.
• Dependence on Scilex: Historically, Semnur's financial statements were derived from Scilex Holding Company, its former parent. This means the reported costs might not fully reflect what Semnur would incur operating entirely independently. Semnur expects to continue relying on Scilex for certain services and limited funding post-merger.
• Contingent Merger Obligations: The original 2019 merger agreement with Legacy Semnur includes potential future payments from Semnur to former Legacy Semnur shareholders (or Scilex) if SP-102 achieves specific cumulative net sales milestones: $100 million, $250 million, $500 million, and $750 million. A 2013 royalty agreement also requires payments of 1.5% or 2.5% of net sales. Crucially, none of these sales milestones or royalty payments have been triggered yet, meaning these represent future obligations, not current income for Semnur.

3. Management Discussion and Analysis (MD&A) Highlights

Management's discussion primarily focuses on the significant corporate transformation in 2025 and the resulting financial and operational challenges.

• Results of Operations: Management highlighted the absence of product revenue in 2025, consistent with the company's clinical-stage status. Substantial operating and net losses primarily stemmed from significant non-cash general and administrative expenses incurred directly from the Business Combination, including substantial consulting fees paid in shares and the write-off of deferred offering costs. R&D expenses increased as the company advanced its lead product candidate, SP-102.
• Liquidity and Capital Resources: A critical focus of management's discussion is the company's precarious liquidity position. With only $20 thousand in cash at year-end and projected operating expenses of approximately $21.0 million for the next twelve months, management emphasized a severe funding gap. The failure to close two anticipated financing deals totaling $120.0 million represented a major setback, necessitating an urgent and active pursuit of alternative financing. The existence of $3.5 million in short-term promissory notes, with potential acceleration clauses, further complicates the capital structure.
• Significant Events and Trends: The successful Business Combination marked a pivotal corporate milestone, establishing Semnur as a public entity. However, this was immediately followed by the significant challenge of delisting from Nasdaq to the OTCQB, which management acknowledges impacts market visibility and liquidity. The inability to secure anticipated financing deals represents a critical setback to the company's capital strategy and its ability to fund future operations.
• Strategic Focus: Post-merger, the company's strategy entirely centers on the development and eventual commercialization of SP-102. Management focuses on building the necessary infrastructure for a public company, including establishing new stock option plans and consulting agreements, while relying on a Transition Services Agreement with Scilex for certain administrative functions during this transitional period.

4. Financial Health

Semnur's financial health is extremely precarious, raising substantial doubt about its ability to continue operations without immediate and significant new funding.

• Critically Low Cash: As of December 31, 2025, Semnur held a mere $20 thousand in cash and cash equivalents. This represents an alarmingly low amount for a public company, especially one in the development stage.
• High Cash Burn: The company used $5.9 million in cash for its day-to-day operations during 2025.
• Short-Term Debt: Semnur carries $3.5 million in promissory notes, all due within the next 12 months. These notes also contain a clause that could trigger immediate repayment if Semnur secures other significant financing, potentially complicating future fundraising efforts.
• Massive Funding Gap: Semnur estimates its operating expenses for the next twelve months will reach approximately $21.0 million, with about $10.0 million allocated to clinical development. With only $20 thousand in cash and an estimated $21 million needed, the company faces a $20.98 million funding gap.
• Limited Scilex Support: While Semnur expects to receive approximately $2.0 million in continued support from Scilex through a Transition Services Agreement, this amount is grossly insufficient to cover its projected needs. This support is also temporary.

These figures paint a dire picture, indicating a high risk that the company will run out of cash in the near future without substantial new capital.

5. Risk Factors

Investors in Semnur Pharmaceuticals face a multitude of high-impact risks:

• Going Concern Risk: The most immediate and critical risk is the company's ability to continue operating. With only $20 thousand in cash and an estimated $21 million needed for the next year, Semnur faces a severe funding shortfall.
• Failed Financing & Capital Needs: The failure to close $120 million in anticipated financing is a major red flag. Semnur urgently needs significant capital to fund its operations and SP-102 development. There is no guarantee it will secure this funding on favorable terms, or at all.
• Reliance on SP-102: The company's future almost entirely depends on the successful clinical development, regulatory approval, and commercialization of SP-102. Clinical trials are inherently risky, and the company offers no assurance of success or timely approval.
• Regulatory Pathway Risk: While the 505(b)(2) pathway can be faster, success is not guaranteed. The FDA may still require additional studies or deny approval.
• Market Listing & Liquidity: Trading on the OTCQB marketplace means lower liquidity, potentially making it difficult for investors to sell shares quickly without impacting the price. It also reduces the company's visibility and attractiveness to institutional investors.
• High Burn Rate: The company's significant operating losses and cash used in operations indicate a high burn rate that is unsustainable without continuous external funding.
• Promissory Note Obligations: The $3.5 million in short-term debt, coupled with the acceleration clause, adds immediate financial pressure and complexity to fundraising.
• Dependence on Scilex: While Scilex provides some transitional support, Semnur's historical financials were derived from Scilex, meaning standalone costs could be higher. The limited and temporary nature of Scilex's financial support is a concern.
• Significant Dilution Risk: If Semnur successfully raises equity financing, it will likely involve issuing a large number of new shares, significantly diluting the ownership and value of existing shareholders.
• Internal Control Weaknesses: As a smaller reporting company, Semnur has not yet filed a report confirming the effectiveness of its internal financial controls. While common for smaller entities, this can raise questions about the reliability of financial reporting.
• Competition: The pain management market is highly competitive, with established players and new therapies constantly emerging. Semnur will need to demonstrate a clear competitive advantage for SP-102.

6. Competitive Position

Semnur operates in a highly competitive pain management market.

7. Future Outlook

Semnur Pharmaceuticals anticipates incurring significant expenses and operating losses for the foreseeable future as it continues to develop SP-102.

• Long Road to Commercialization: The company's future heavily depends on the successful and timely development, regulatory approval, and commercial launch of SP-102. The contingent sales milestones mentioned earlier remain distant and uncertain.
• Active Pursuit of Financing: Given its critical cash position, Semnur actively explores various financing alternatives, including new credit facilities, non-dilutive financing (e.g., collaborations, royalty deals), debt financing, and equity financing (selling more shares). This indicates an urgent and immediate need for substantial capital to sustain operations.
• Uncertainty of Success: There is no guarantee that Semnur will secure the necessary funding or successfully bring SP-102 to market.

In summary, Semnur Pharmaceuticals, Inc. is a high-risk, high-potential biopharmaceutical company in a critical financial position. While the merger provided a public platform for SP-102, the company faces an immediate and significant funding gap, relies on a single product candidate, and navigates the challenges associated with its OTCQB listing. Investors should proceed with extreme caution and conduct thorough due diligence.